warneford healthcare

What warneford healthcare does

Warneford Healthcare is a privately held UK pharmaceutical company headquartered in Weybridge, Surrey, that develops and markets a branded ophthalmology portfolio spanning preservative-free multi-dose eye drops, ocular ointments, and ocular-nutrition capsules. Its core technology centers on multi-dose delivery platforms — notably its proprietary Ophthalmic Squeeze Dispenser (OSD), used in the PF Drops range, and the AeroPump system used in ClinOptic HA — which allow preservative-free formulations to remain sterile and usable for 56-180 days after first opening while delivering higher drop counts per unit than standard droppers. The product set covers dry eye (PF Drops Carmellose, Hypromellose, Sodium Chloride, Sodium Hyaluronate; ClinOptic HA; Eyenite; Eyezin XL), allergic eye (Librachrom, Eycrom), anti-inflammatory and anti-infective segments (Puradex dexamethasone, Eyflox levofloxacin), and ocular nutrition (Glaucomin nicotinamide capsules).

The company operates a sales-led go-to-market. The primary enterprise customer is the UK NHS, where products are positioned as quality cost-saving alternatives to originator brands and listed on the NHSBSA schedule (e.g., Glaucomin at an NHS List Price of £5.55 for a 30-day supply). Healthcare professionals (ophthalmologists, GPs, optometrists) prescribe or recommend products, while patient-direct revenue is captured via the Penlan Healthcare e-commerce storefront and a retail partnership with Butterflies Eyecare. Outside the UK, Warneford extends reach through an international partner network rather than owned subsidiaries. No revenue, funding, M&A, or leadership-change data is disclosed; the company appears to be bootstrapped, founder-led, and operating without institutional capital backing.

Name

warneford healthcare

Legal name

Warneford Healthcare Ltd

Website

https://warnefordhealth.com

Company type

Private

Operating status

Operating

Short description

UK-based pharmaceutical company developing and marketing branded ophthalmology products — primarily preservative-free multi-dose eye drops plus ocular-nutrition capsules — sold to the NHS, healthcare professionals, and patients via e-commerce and an international partner network.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Ophthalmic Goods Manufacturing (339115), Ophthalmic Goods Merchant Wholesalers (423460), Optical Goods Retailers (45613)

SIC

Ophthalmic Goods (3851), Pharmaceutical Preparations (2834)

akta.pro primary industry

Ophthalmic & Otic Generics (HLAIABAF)

akta.pro secondary industries

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Ophthalmology Pharmaceuticals (HLAIAAAL)

Keywords

• Ophthalmology pharmaceuticals
• Preservative free eye drops
• Ocular nutrition supplements
• Multi-dose eye drops
• Generic ophthalmic products

Headquarters

HQ city

Weybridge

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Warneford Healthcare generates revenue through the sale of ophthalmology pharmaceutical products including eye drops, eye ointments, and nutritional supplements. Products are sold both for NHS prescription and direct patient purchase through e-commerce and retail partners.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Warneford Healthcare develops and markets a portfolio of ophthalmic pharmaceutical products, primarily preservative-free multi-dose eye drops and ocular lubricants for conditions including dry eye, infections, inflammation, and glaucoma, alongside ocular nutrition supplements. Two distinct audience tracks are served: a healthcare-professional / NHS prescription track and a direct-to-patient track, both powered by proprietary multi-dose delivery technology (AeroPump and OSD) that preserves sterility for extended in-use periods.

Product overview

Warneford Healthcare is a pharmaceutical company specializing in ophthalmology products that enhance patient well-being. The product portfolio consists of preservative-free multi-dose eye drops and ocular lubricants organized under two main sub-brands: the PF Drops range (Carmellose Sodium, Hypromellose, Sodium Chloride, and Sodium Hyaluronate formulations) and branded products including ClinOptic® HA, Eyenite®, Eyezin® XL, Glaucomin™, Librachrom®, Puradex®, Eyflox®, and Eycrom®. These products address conditions including dry eye, infections, inflammation, glaucoma, and provide ocular nutrition. The offerings are divided into patient-facing products (available for direct purchase) and healthcare professional products (prescribable), with specific formulations and concentrations tailored to each segment.

Differentiator

Problem solved

Functional benefit

Brands

• PF Drops: Preservative free eye drops range including Carmellose Sodium, Hypromellose, Sodium Chloride, and Sodium Hyaluronate formulations.
• ClinOptic
• Eyenite
• Eyezin
• Glaucomin
• Librachrom
• Puradex
• Eyflox
• Eycrom

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Butterflies EyecarecoreChannel Partner/ Reseller/ DistributorButterflies Eyecare (butterflies-eyecare.co.uk) serves as the primary retail partner for Warneford Healthcare, selling patient products including Eyenite eye ointment, Eyezin XL eye drops, PF Drops product range, and ClinOptic HA eye drops directly to consumers through their e-commerce platform.
• Penlan HealthcarecoreChannel Partner/ Reseller/ DistributorPenlan Healthcare operates the e-commerce platform (penlanhealthcare.com) where products including ClinOptic HA and Glaucomin capsules are available for purchase. The domain is linked to the Warneford Healthcare brand.
• International PartnersminorChannel Partner/ Reseller/ DistributorWarneford Healthcare operates in many countries outside of the UK through International Partners, extending geographic reach beyond domestic UK market.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Alcon: Global leader in eye care with surgical and pharmaceutical franchises including ophthalmic drops and ocular surface treatments. Comparable to Warneford in pharmaceutical ophthalmology but operates at much larger scale and global footprint.
• Bausch + Lomb: Global ophthalmology incumbent with a broad portfolio spanning pharmaceuticals, lenses, and surgical devices. Overlaps with Warneford in ophthalmic pharmaceuticals (artificial tears, anti-infectives, anti-inflammatories) but operates at vastly greater scale and broader scope.
• Teva Pharmaceutical Industries: Global generics giant with a meaningful ophthalmology portfolio including preservative-free and multi-dose eye drops. Directly comparable to Warneford in competing on cost-effective generic ophthalmic formulations across the NHS and European markets.
• AbbVie (Allergan Aesthetics / Eye Care): Owns the historic Allergan ophthalmology franchise covering dry eye (Restasis), glaucoma, and allergy. Competes with Warneford in ophthalmic prescription pharmaceuticals while also providing the originator products that Warneford positions against as cost-effective generics.

Emerging players

• Nicox: European ophthalmology specialty company developing therapeutics for glaucoma and ocular surface disease. Comparable to Warneford as a smaller specialist focused on ophthalmic pharma, though more R&D-driven and pre-commercial in several assets.
• Scope Ophthalmics: UK and Ireland-based specialty eye care company focused on dry eye, lid hygiene, and ocular surface products. Comparable to Warneford in serving ophthalmologists, optometrists, and patients in the UK with non-prescription and specialty ocular products.

Direct peers

• Santen Pharmaceutical: Japan-headquartered specialty ophthalmology pharmaceutical company with a strong European presence in dry eye, glaucoma, and allergy. Comparable to Warneford as a focused ophthalmology pharma selling prescription and OTC eye drops across similar therapeutic categories.
• Théa Pharmaceuticals: Independent European ophthalmology specialty company focused on preservative-free eye drops and ocular surface disease. Directly comparable to Warneford's preservative-free PF Drops and ClinOptic portfolios targeting dry eye and ophthalmology prescribers.

Regional players

• Hikma Pharmaceuticals: UK-listed generics pharmaceutical company with a significant ophthalmology franchise. Comparable to Warneford in supplying generic ophthalmic products to the NHS and MENA markets, though Hikma is much larger and more diversified across therapeutic areas.
• Martindale Pharma (Esteve): UK-based specialty pharmaceutical company now part of Esteve, with hospital and ophthalmology products sold to the NHS. Comparable to Warneford as a UK-headquartered pharma selling ophthalmic and related products into NHS channels.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about warneford healthcare